Analyse BioNTech (ADRs) stock

Plausibility assessment: The consensus price target of 135.56 EUR is around 59% above the current price of 85.25 EUR and therefore outside the required range of +/-25%. An adjusted price target of EUR 118.00 is more plausible based on fundamentals, pipeline optionality and historical volatility.

Quantitative: BioNTech is currently valued at a negative P/E ratio (-16.92) despite high liquidity and a strong balance sheet, which shows that the market is pricing in the transition from pandemic profits to a research-driven earnings gap. The share is trading well below previous valuation levels; At the same time, the adjusted ta...